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Abstract 
 Background and Aims: Left ventricular systolic dysfunction, even 
asymptomatic, is associated with the development of heart failure (HF) and 
all-cause mortality. Left ventricular ejection fraction (LVEF) is the most 
commonly used marker of left ventricular systolic function. It is well 
established that early detection and treatment of reduced LVEF, as well as 
the aggressive management of predisposing conditions, delays the 
manifestation of HF. Our study aimed to measure the association between 
LVEF and other echocardiographic variables in a population with LVEF 
within the normal range and without symptoms of HF. Methods: We 
conducted a cross-sectional study in 2008-2009. Results: We analyzed 
echocardiographic and clinical data of 146 patients: 66.4% were women; 
mean age was 55 (40 –69 years). LVEF significantly correlated only with 
left atrium (LA) size (Beta -0.266, p < 0.05). The correlation was inverse and 
remained significant after adjusting for age, gender, obesity, diabetes, arterial 
hypertension, left ventricular hypertrophy, pulmonary systolic pressure, 
mitral regurgitation, and diastolic dysfunction. Conclusions: We found that 
the earliest structural change associated with LVEF tendency to decrease was 
LA size. Further research is needed to assess the LA enlargement as an early 
predictor of systolic dysfunction development.  
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Introduction 
 Left ventricular systolic dysfunction, even asymptomatic, is a high 
risk for development of heart failure (HF), coronary vascular disease (CVD) 
and all-cause mortality [Yeboah J. et al., 2012, Abhayarantna W. P, 2012, 
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Kardys I. et al., 2010, Reddy K et al., 2004]. The development of systolic 
dysfunction indicates the progression to the C stage of HF and predicts the 
occurrence of HF symptoms [Echouffo-Tcheugui JB, Erqou S, Butler J, 
Yancy CW, Fonarow GC., 2016, Echouffo-Tcheugui JB, Erqou S, Butler J, 
Yancy CW, Fonarow GC, 2015]. Left ventricular ejection fraction (LVEF ) 
is the most commonly used marker of left ventricular systolic function 
[Abhayarantna W. P, 2012, Carerj S, et al., 2010,  Laure MS, Evans JC, 
Levy D, 1992]. Early detection and treatment of reduced LVEF, as well as 
the aggressive management of well-established predisposing conditions of 
HF, delays the manifestation of HF [Echouffo-Tcheugui et al, 2016, 
Echouffo-Tcheugui et al, 2015, Nanayakkara S Kaye DM, 2015, Yusuf S, 
Pitt B, Davis CE, Hood WB Jr, Cohn JN, 1992]. 
 The predisposing conditions of HF include CVD, smoking, arterial 
hypertension, obesity, diabetes, valvular heart disease, and male sex [He J et 
al., 2001, Baldasseroni S, et al., 2002].  
 Among patients, without HF symptoms traditional cardiovascular 
risk factors correlate with echocardiographic parameters [Rukhadze E, 
Bregvadze-Tabagari N, Tvildiani L, 2016, Kardys I. et al., 2010]. 
Echocardiography has an additional value in the prediction of HF 
progression and the development of cardiovascular events [Abhayarantna W. 
P, 2012, Carerj S, et al., 2010,  Laure MS, Evans JC, Levy D, 1992]. 
 This paper describes further analysis of the data collected as part of 
our study published in 2016 and 2017 [Rukhadze E, Bregvadze-Tabagari N, 
Tvildiani L, 2016] and between echocardiographic characteristics and the 
CVD risk groups defined by WHO (World Health Organization) /ISH 
(International Society of Hypertension)  [Rukhadze E, Bregvadze-Tabagari 
N, Tvildiani L, 2017].    
 Our study aimed at measuring the association between LVEF and 
other echocardiographic variables in a population without symptoms of HF 
and preserved LVEF. 
 
Material and Method  
 The population of our study is a subpopulation of a larger study 
[Shanthi M, 2005, Toidze M, Tabagari S, Mendis S, Norder P, Bregvadze-
Tabagari N, Tvildiani L, Phkhaladze G, Talakvadze T, 2012]. We conducted 
a cross-sectional study in Sachkhere Medical Center in Georgia from 
September 2008 to December 2010. The study protocol was approved by the 
Sachkhere Medical Center and David Tvildiani Medical University Ethics 
committees. Participation was voluntary. All participants gave written 
informed consent. 
 The study group included 177 participants without clinically 
manifested cardiovascular disease, who underwent routine transthoracic 
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echocardiography during the period of “Cardiovascular Risk Assessment of 
the Georgian Population study” [Toidze M et al., 2012]. We excluded 31 
(17.5%) participants from our analysis.  For Exclusion we used the following 
criteria:  LVEF < 50 %, severe valvular heart disease defined by European 
Association of Echocardiography (EAE) and American Society of 
Echocardiography (ASE) recommendations [ASE COMMITTEE 
RECOMMENDATIONS for Chamber Quantification, 2005], and atrial 
fibrillation. 
 Out of 146 participants included in the final statistical analysis, ??? 
(66.4%) were women; mean age was 55 (40 –69 years). 
 
Assessment of CVD risk factors 
 For hypertension we used Joint National Committee (JNC 7) 
definitions [ESC Committee for Practice Guidelines to improve the quality 
of clinical practice and patient care in Europe, 2007]; Hyperlipidemia was 
defined as fasting total cholesterol ≥ 5.2 mmol/L (≥200 mg/dl); diabetes was 
defined as fasting glucose ≥ 7mmol/L (≥ 126 mg/dl) or use of insulin or oral 
hypoglycemic medications. Persons who smoked regularly during the 
previous 12 months were classified as smokers. 
 
Echocardiography assessment 
 We performed Echocardiography on Philips Sonos 7500 with 
Secondary Harmonic Imaging by the recommended technique for 
transthoracic quantitative evaluations [ASE COMMITTEE 
RECOMMENDATIONS for Chamber Quantification, 2005]. 
 We assessed the mean values and correlation of the following 
echocardiographic characteristics: left ventricular end-diastolic diameter 
(LVEDD), interventricular wall thickness (IWS), posterior wall thickness 
(PWT), left ventricular end-diastolic volume (LVEDV), left ventricular 
ejection fraction (LVEF), left atrium diameter (LAD), and pulmonary 
systolic pressure (PSP).  
 We evaluated Left ventricular systolic function by the method of 
discs (Simpson’s rule) - using area tracings of the LV cavity [ASE 
COMMITTEE RECOMMENDATIONS for Chamber Quantification, 2005]. 
For the LA measure, we used LA anteroposterior linear dimension in the 
parasternal long-axis view by 2 Dimensional (2D) echocardiography [ASE 
COMMITTEE RECOMMENDATIONS for Chamber Quantification, 2005]. 
The PSP was assessed by continuous-wave Doppler of tricuspid 
regurgitation [Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg 
E, 1985]. For assessment of left ventricular diastolic function, we analyzed 
mitral inflow patterns defined by pulsed wave (PW) Doppler. Additionally, 
in some cases, we used PW tissue Doppler (DTI) for assessment mitral 
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annular early and late diastolic velocities [Recommendations for the 




 We analyzed the data using IBM SPSS Statistics version 21. 
Descriptive statistics (means, standard deviations, and proportions) were 
calculated for cardiovascular risk factors and echocardiographic 
characteristics. Linear regression method was used to establish correlations 
between EF and other echocardiographic variables. A p-value <0.05 was 
defined as statistically significant.  
 
Results 
Our study p opulation is described in table 1.  
Most of our participants were women; age varied from 40 to 69 (mean age 
55). Obesity (OB) was present in 56.80 % of study population; Diabetes 
Mellitus (DM) (12.30 %); Hyperlipidemia (19.20 %); Smoking (11.60 %); 
Arterial hypertension (47.30 %).  
LA, Left atrium diameter; LVD, Left ventricular end-diastolic dimension; IVS, 
Interventricular septum thickness; PWT, Left ventricular posterior wall thickness; LVEDV, 
Left ventricular end-diastolic volume; LVEF, Left ventricular ejection function; PSP, 
Pulmonary Systolic Pressure; MR, Mitral regurgitation; DF, Diastolic function, LVH, Left 
ventricular hypertrophy. 
Table 1. Demographic, Clinical and Echocardiographic Characteristics (N=146) 
Characteristic Count (%) 
 Women 97 (66.4) 
 Obesity  93 (56.8)  
 Diabetes Mellitus  18 (12.3)  
 Hyperlipidemia 28 (19.2) 
 Smoking 17 (11.6) 
 Arterial Hypertension 69 (47.3) 
 LVH  7 (4.8)  
 DF (impaired relaxation / pseudonormal) 124 (84.9)  
 MR (1st degree / 2nd degree)  146 (94.5)  
 Mean (SD) 
 Age, year  54.75 (8.9)    
 IVS (mm) 10.4 (1.5) 
 PWT (mm) 10.3 (1.5) 
 LA diameter (mm)  40.8 (4.5)  
 PSP (mmHg)  28.3 (9.5)  
 LVD (mm) 48.9 (4.6) 
 LVEDV (ml) 102.2 (24.7) 
 LVEF (%)   61.5 (4.9)  
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Mean values of all evaluated echocardiographic variables (LVD, 
IVS, LVEDV, PSP and EF) except LA were in the normal range, while LA 
diameter was slightly increased (normal value < 40 mm). Left ventricular 
Hypertrophy (LVH) defined by left ventricular wall thickness was present 
only in 4.8 % of study population.  Left ventricular diastolic dysfunction 
(impaired relaxation and pseudonormal type) was presented in 84.9 % of 
the study population, mitral regurgitation (first and second degree – 94.5 %.  
 
 In table 2 is represented the correlation between LVEF and some of 
the traditional CVD risk-factors and echocardiography characteristics. The 
LVEF significantly correlated only with LA diameter (inverse correlation).  
This correlation remains significant (Beta -0.266, p < 0.05) after adjusting 
for age, gender and presence or absence Obesity, Diabetes Mellitus, Arterial 
Hypertension and echocardiography defined left ventricular hypertrophy, 
Pulmonary Systolic pressure, and presence or absence mitral regurgitation 
and diastolic dysfunction. 
Table 2. Correlation of LVEF with CVD risk-factors and echocardiography characteristics. 
Characteristics Beta p-value 
  LA -0,266 0,032 
 Age -0,054 0,572 
 Gender 0,060 0,498 
 Obesity  0,027 0,756 
 Diabetes Mellitus  -0,067 0,436 
 Arterial Hypertension -0,094 0,283 
 LVH 0,039 0,654 
 Hyperlipidemia 0,042 0,627 
 MR 0,014 0,900 
 DF 0,115 0,317 
 PSP -0,111 0,265 
LA, Left atrium diameter; LVD, LVEF, Left ventricular ejection function; PSP, Pulmonary 




 Our study revealed there is a strong correlation between LA size and 
EF in a population without any clinical presentation of HF, with a slightly 
increased mean LA size, but a reserved mean EF. The correlation remains 
significant after adjusting for age, echocardiography evaluated LVH, the 
presence of Diabetes Mellitus and Obesity. As it was mentioned in our 
previous studies, LA was the echocardiographic variable that correlated with 
most CVD risk factors (age, BMI, WC, SBP, and TCH). Age and obesity 
variables (WC and BMI) correlated with most of the echocardiographic 
characteristics [Rukhadze E, Bregvadze-Tabagari N, Tvildiani L, 2016]; In 
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different WHO-ISH risk groups, statistically significant differences were 
established for LA, PSP, and EF: LA and PSP increased from low to high-
risk groups, while EF decreased, but remained in normal range. 
 It means LA enlargement is a more sensitive marker than EF 
reduction, can occur earlier, and may be considered as an early predictor of 
systolic dysfunction.  
 The prognostic role of left atrial enlargement was the subject of 
several recent studies. The role of LA volume as a marker for severity and as 
a significant independent predictor of LV diastolic dysfunction is well 
established [Paulus WJ et al, 2007, Lim TK, Ashrafian H, Dwivedi G, 
Collinson PO, Senior R, 2006, Douglas PS, 2003, Tsang TS, Barnes ME, 
Gersh BJ, Bailey KR, Seward JB, 2002]. There are also studies which 
revealed  that LA size and volume are as strong a predictor of death and 
other cardiovascular events in a general population  as in patients with a 
variety of cardiac diseases [Bombelli M et al, 2014, Rossi A et al, 2009, 
Patel D,  Lavie C, Milani, R, Shah S, Gilliland Y, 2009, Laukanen JA, Kurl 
S, Eranen J, Huttunen M, Salonen JT, 2005,  Rossi A et al, 2002, Rossi A et 
al 2000].  
 According to the results of PAMELA study, which estimated the risk 
of cardiovascular events, cardiovascular mortality, and all-cause mortality 
associated with the LA enlargement alone or combined with 
echocardiographic LVH in 1,785 representatives of the general population,  
subjects with isolated LA enlargement exhibited a significant increase in the 
adjusted risk of combined fatal and nonfatal cardiovascular events [Bombelli 
M et al, 2014].  
 Similar results were obtained in CARDIA study, which included 
young adults above the clinically established Framingham 10-year global 
CV risk score. The combined endpoint (incident fatal or non-
fatal cardiovascular disease: myocardial infarction, heart failure, 
cerebrovascular disease, peripheral artery disease, atrial fibrillation/flutter) 
was determined after 20 years. LA size measurements independently 
predicted the clinical outcomes, but without altering risk classification 
[Armstrong A et al., 2014].  
 We can conclude LA enlargement can be considered an early 
predictor of reducing EF and thus developing systolic dysfunction. Further 
studies needed to assess the cost effectiveness of routine echocardiographic 
examination of patients without clinical manifestation of HF.  In patients 
with increased LA size, but otherwise normal structural echocardiographic 
parameters, risk modification should be more aggressive to delay the 
manifestation of HF.  Additional study is needed to confirm our hypothesis. 
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